Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 30:12:1756287220937232.
doi: 10.1177/1756287220937232. eCollection 2020 Jan-Dec.

A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men

Ronald S Swerdloff  1 , Robert E Dudley  2
Affiliations

A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men

Ronald S Swerdloff et al. Ther Adv Urol. .

Erratum in

Abstract

Background: A novel formulation of oral testosterone undecanoate (TU) was studied in a long- and short-term phase III trial to evaluate safety and efficacy.

Methods: Hypogonadal men (age 18-65 years; two morning serum testosterone (T) <300 ng/dl with signs/symptoms) were recruited into a 365 day (trial I) or 105 day (trial II), randomized, multicenter trial. Patients were randomized 1:1 to oral TU (n = 161) or T-gel (n = 160) in trial I, and 3:1 to oral TU, twice daily (BID) JATENZO® (n = 166) or a topical T product [Axiron® (n = 56)] in trial II. Dose adjustments were based on average T concentrations (Cavg). Efficacy was assessed based on T levels, body composition and bone density. Safety was assessed by standard clinical measures.

Results: Oral TU efficacy (% of patients with eugonadal T Cavg) was 84% (serum Cavg = 628 ± 343 ng/dl) and 87% (serum T equivalent Cavg ≈ 489 ± 155 ng/dl) in trials I and II, respectively. Oral TU significantly (p <0.0001) improved all Psychosexual Daily Questionnaire parameters in trials I and II. In trial I, lean mass increased 3.2 ± 2.7 kg and fat decreased by 2.4 ± 3.6 kg (both p <0.0001) and bone density improved in hip (+0.012 ± 0.0225 g/cm2) and spine (+0.018 ± 0.0422 g/cm2) after 365 days (both p <0.0001). Oral TU-associated adverse effects were consistent with other T-replacement therapies but oral TU patients experienced a greater number of mild gastrointestinal adverse effects. Oral TU subjects in both studies exhibited an increase in mean systolic blood pressure of about 3-5 mmHg. Oral TU was not associated with liver toxicity nor did it cause an elevation in high-sensitivity C-reactive protein or lipoprotein-associated phospholipase A2 (cardiovascular safety biomarkers) after 365 days of therapy.

Conclusion: A new oral TU formulation was safe and effective and represents a significant therapeutic advance for the treatment of appropriate hypogonadal men.

Keywords: male hypogonadism; testosterone; testosterone undecanoate.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: RSS served as principal investigator for studies CLAR-09007 (trial I) and CLAR-15012 (trial II) that were funded by Clarus Therapeutics, Inc. RSS has also received support from the NIH for testosterone studies in older men, and currently receives support from AbbVie as a study site for the Traverse Study of testosterone gel. He has also received support from NIH and NICHD for studies on male contraception where testosterone was a component of the experimental therapy. RED is employed by Clarus Therapeutics, Inc. (a private firm) and has an equity stake in the company.

Figures

Figure 1.
Figure 1.
Pictorial representation of TU lymphatic absorption after oral delivery in SEDDS formulation. SEDDS, self-emulsifying drug delivery system; TU, testosterone undecanoate.
Figure 2.
Figure 2.
Mean concentration–time profiles for total serum T in patients treated with oral TU at final PK visit in trial I, and for NaF-EDTA plasma total T in patients treated with oral TU at final PK visit in trial II. (a) Mean (±SE) concentration–time profiles for total serum T in patients treated with oral TU at final PK visit (day 90) in trial I; (b) mean (±SE) concentration–time profiles for NaF-EDTA plasma total T in patients treated with oral TU at final PK visit (day 90/105) in trial II*. *Values in graph can be converted to approximate serum T equivalents by multiplying by 1.214. Mean T Cavg in serum = 403 ± 128 ng/dl × 1.214 (correction factor) ≈ 489 ± 158 ng/dl serum T units. Data published previously. Cavg, average T concentrations; NaF-EDTA, sodium fluoride-ethylenediaminetetraacetic acid; PK, pharmacokinetics; SE, standard error; T, testosterone; TU, testosterone undecanoate.
Figure 3.
Figure 3.
Effect of oral TU on change from baseline in psychosexual function (PDQ) responses over the 4-month treatment period in trial I. PDQ, Psychosexual Daily Questionnaire; SD, standard deviation; TU, testosterone undecanoate.
Figure 4.
Figure 4.
Effect of 6- and 12-month oral TU therapy on mean (±) changes from baseline in lean body mass and fat mass in trial I. TU, testosterone undecanoate.
See this image and copyright information in PMC

References

    1. Nieschlag E, Nieschlag S. Endocrine history: the history of discovery, synthesis and development of testosterone for clinical use. Eur J Endocrinol 2019; 180: R201–R12. - PubMed
    1. Foss GL, Simpson SL. Oral methyltestosterone and jaundice. Br Med J 1959; 1: 259–263. - PMC - PubMed
    1. Shackleford DM, Faassen WA, Houwing N, et al. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two Andriol formulations in conscious lymph duct-cannulated dogs. J Pharmacol Exp Ther 2003; 306: 925–933. - PubMed
    1. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008; 154: 502–521. - PMC - PubMed
    1. Westaby D, Ogle SJ, Paradinas FJ, et al. Liver damage from long-term methyltestosterone. Lancet 1977; 2: 262–263. - PubMed